| Dr Debra Ellen Cressman, MD | |
|
215 N Best Ave, Walnutport, PA 18088-1204 | |
| (610) 760-7044 | |
| (610) 760-8587 |
| Full Name | Dr Debra Ellen Cressman |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 35 Years |
| Location | 215 N Best Ave, Walnutport, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386790590 | NPI | - | NPPES |
| MD045718L | Other | PA | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD045718L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Lehigh Valley Hospital | Allentown, PA | Hospital |
| St Luke's Miners Memorial Hospital | Coaldale, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cressman And Yablonski | 4082652979 | 2 |
News Archive
The Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford today announced that it will host the 11th Annual Race Against PH in conjunction with the Pulmonary Hypertension Association's 6-Minute Marathon. These events provide patients with an opportunity to walk or jog alongside their families and friends, to help increase awareness of the disease, and to help raise money to find a cure.
Amedica Corporation, an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, is pleased to announce all four submissions to the International Society for Technology in Arthroplasty were accepted for presentation during the 28th annual congress occurring September 30 – October 3, 2015 in Vienna, Austria.
Researchers from Seattle Children's Research Institute and the University of Washington described a high-throughput and rapid technique to quantify circulating levels of functional antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the entire viral spike protein should be used to characterize the immune response. Their paper is currently available on the medRxiv* preprint server.
The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.
› Verified 4 days ago
| Entity Name | Cressman And Yablonski |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295872901 PECOS PAC ID: 4082652979 Enrollment ID: O20050421000108 |
News Archive
The Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford today announced that it will host the 11th Annual Race Against PH in conjunction with the Pulmonary Hypertension Association's 6-Minute Marathon. These events provide patients with an opportunity to walk or jog alongside their families and friends, to help increase awareness of the disease, and to help raise money to find a cure.
Amedica Corporation, an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, is pleased to announce all four submissions to the International Society for Technology in Arthroplasty were accepted for presentation during the 28th annual congress occurring September 30 – October 3, 2015 in Vienna, Austria.
Researchers from Seattle Children's Research Institute and the University of Washington described a high-throughput and rapid technique to quantify circulating levels of functional antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the entire viral spike protein should be used to characterize the immune response. Their paper is currently available on the medRxiv* preprint server.
The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Debra Ellen Cressman, MD 215 N Best Ave, Walnutport, PA 18088-1204 Ph: (610) 760-7044 | Dr Debra Ellen Cressman, MD 215 N Best Ave, Walnutport, PA 18088-1204 Ph: (610) 760-7044 |
News Archive
The Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford today announced that it will host the 11th Annual Race Against PH in conjunction with the Pulmonary Hypertension Association's 6-Minute Marathon. These events provide patients with an opportunity to walk or jog alongside their families and friends, to help increase awareness of the disease, and to help raise money to find a cure.
Amedica Corporation, an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, is pleased to announce all four submissions to the International Society for Technology in Arthroplasty were accepted for presentation during the 28th annual congress occurring September 30 – October 3, 2015 in Vienna, Austria.
Researchers from Seattle Children's Research Institute and the University of Washington described a high-throughput and rapid technique to quantify circulating levels of functional antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that the entire viral spike protein should be used to characterize the immune response. Their paper is currently available on the medRxiv* preprint server.
The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.
› Verified 4 days ago
Thomas Edward Yablonski, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 215 N Best Ave, Walnutport, PA 18088 Phone: 610-760-7044 Fax: 610-760-8587 | |
Lisa Jill Doherty, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 330 N Best Ave, Walnutport, PA 18088 Phone: 610-760-8080 Fax: 610-760-8148 | |
Colleen Manzella, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 330 N Best Ave, Walnutport, PA 18088 Phone: 610-760-8080 Fax: 610-760-8148 |